VIVAC

Viscogel - A chitosan based adjuvant for prophylactic and therapeutic vaccination

Coordinatore	Viscogel AB    more  Organization address address: Gunnar Asplunds Alle 32 city: Solna postcode: 17163 contact info Titolo: Mr. Nome: Lars-Erik Cognome: Andersson Email: send email Telefono: 46768880624 Fax: 4687303998
Nazionalità Coordinatore	Sweden [SE]
Totale costo	1˙496˙400 €
EC contributo	1˙155˙362 €
Programma	FP7-SME Specific Programme "Capacities": Research for the benefit of SMEs
Code Call	FP7-SME-2010-1
Funding Scheme	BSG-SME
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-09-01   -   2012-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	Viscogel AB  Organization address address: Gunnar Asplunds Alle 32 city: Solna postcode: 17163 contact info Titolo: Mr. Nome: Lars-Erik Cognome: Andersson Email: send email Telefono: 46768880624 Fax: 4687303998	SE (Solna)	coordinator	735˙596.50
2	Inmunotek SL  Organization address address: Calle Velazquez 124 city: Madrid postcode: 28006 contact info Titolo: Dr. Nome: José L. Cognome: Subiza Email: send email Telefono: +34 916 510 010 Fax: +34 916 639 732	ES (Madrid)	participant	293˙343.75
3	Lytix Biopharma AS  Organization address address: Sykehusveien 23 city: Tromso postcode: 9294 contact info Titolo: Dr. Nome: Anders Cognome: Fuggeli Email: send email Telefono: +47 77 67 55 00	NO (Tromso)	participant	126˙422.25
4	HACETTEPE UNIVERSITESI  Organization address address: HACETTEPE UNIVERSITESI BEYTEPE KAMPUSU REKTORLUK BINASI city: CANKAYA ANKARA postcode: 6800 contact info Titolo: Prof. Nome: Sevda Cognome: Senel Email: send email Telefono: +90 312 305 12 41	TR (CANKAYA ANKARA)	participant	0.00
5	Huntingdon Life Sciences Ltd  Organization address address: Woolley Road city: "Alconbury, Huntingdon" postcode: PE28 4HS contact info Titolo: Dr. Nome: Dan Cognome: Gliddon Email: send email Telefono: +44 1480 892544	UK ("Alconbury, Huntingdon")	participant	0.00
6	KAROLINSKA INSTITUTET  Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 contact info Titolo: Dr. Nome: Hans Cognome: Grönlund Email: send email Telefono: +46 704968786	SE (STOCKHOLM)	participant	0.00
7	NORGES TEKNISK-NATURVITENSKAPELIGEUNIVERSITET NTNU  Organization address address: HOGSKOLERINGEN 1 city: TRONDHEIM postcode: 7491 contact info Titolo: Prof. Nome: Kjell Cognome: Vaarum Email: send email Telefono: 4773593324	NO (TRONDHEIM)	participant	0.00
8	PHARMA CONSULTING GROUP IN UPPSALA AB  Organization address address: KUNGSANGSVAGEN 19 city: UPPSALA postcode: 75323 contact info Titolo: Mr. Nome: Sverre Cognome: Bengtsson Email: send email Telefono: +46 708 18 22 84	SE (UPPSALA)	participant	0.00
9	Stallergenes SA  Organization address address: Rue Alexis De Tocqueville 6 city: ANTONY postcode: 92160 contact info Titolo: Dr. Nome: Philippe Cognome: Moingeon Email: send email Telefono: +33 1 55 59 25 20	FR (ANTONY)	participant	0.00
10	STOCKHOLMS LAENS LANDSTING  Organization address address: Hantverkargatan 45 city: STOCKHOLM postcode: 104 22 contact info Titolo: Ms. Nome: Ocklin Cognome: Gertrud Email: send email Telefono: +46 9 517 792 06	SE (STOCKHOLM)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The overall aim of the ViVac project is to develop and to show safety and efficacy for a new innovative carbohydrate (chitosan) based adjuvant -Viscogel –to be used both in prophylactic and therapeutic vaccination. Three SME participants will contribute with their specific technologies: the unique Viscogel technology, a specific type of cationic peptides with cell-penetrating capacity (LTX) and a technology platform for production of recombinant allergens (Bet v 1). Viscogel has excellent adjuvant properties: strongly immunostimulatory, stable, easy to manufacture, pronounced depot effect and possibility to obtain products of GMP quality. In addition Viscogel is mucoadhesive and in combination with LTX cell penetrating, making it suitable for mucosal administration. The target applications to be demonstrated in the ViVac project are i) prophylactic vaccination against common infectious diseases, and ii) therapeutic allergy vaccination. Both application areas represent billion € markets. Five RTD consortium partners with specific key competences will perform research to support further technical development and new IP opportunities for the participating SME partners. The research objectives are i) to provide pre-clinical and clinical proof-of-concept for prophylactic vaccination with a model vaccine against Hib (Haemophilus influenzae type b). Data supporting that Viscogel induces improved immune responses at lower vaccine doses will likely be applicable to most prophylactic vaccines. ii) to provide pre-clinical proof-of-concept for therapeutic vaccination, demonstrated for allergy vaccination. In particular Viscogel-Bet v 1 formulations for administration over the sublingual mucosa will be developed and thus fulfil an unmet medical need for safe, efficient and convenient allergy vaccination. A successful outcome of the ViVac project will significantly improve the competitive situation for the SME partners and create new commercialisation opportunities.'

Introduzione (Teaser)

A European consortium tested the efficacy of a novel carbohydrate-based adjuvant for prophylactic and therapeutic vaccination. Apart from increased efficacy, exploitation of this simple and inexpensive technology enables reduced cost of vaccine production, making them more affordable for developing countries.